BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise

Tvardi Therapeutics

15/05/2025 12:18

** BTIG starts coverage on Tvardi Therapeutics TVRD.O with "buy" rating and $55 PT, 108.7% upside to stock's last close

** Brokerage says TVRD is "presumptive first mover" in developing STAT3 inhibitors for fibrotic diseases, targeting previously "undruggable" protein with "highly validated and well-characterized" profile

** Fibrotic diseases are type of lung illnesses

** Co's lead drug, TTI-101, has potential to be "breakthrough therapy" that can actually reverse these diseases, rather than just slowing their progression, BTIG says

** Says early results from clinical trial are "unusually persuasive", with over 50% of patients showing improvement - outcome that is "unlikely without an active therapy"

** Upcoming mid-stage trial data expected in 2H25 could be major catalyst for stock, BTIG says

** As of last close, stock up 43.5% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))